Buprenorphine Patch, Extended Release
Product Images NDC 50742-376

29 FDA label images from Ingenus Pharmaceuticals, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Buprenorphine (NDC 50742-376). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ingenus Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Table1 Slc 0054)

Image Description (Table1 Slc 0054)
A dose conversion chart showing the recommended starting dose of Buprenorphine Transdermal System based on previous opioid analgesic daily dose in oral morphine equivalent. For doses under 30 mg, the starting dose is 5 mcg/hour; for doses between 30-80 mg, the starting dose is 10 mcg/hour.*
FDA Label Image

Structure (Structure Slc 0054)

Structure (Structure Slc 0054)
Chemical structure of buprenorphine, depicting its molecular formula with detailed ring systems and functional groups including hydroxyl, methoxy, and tertiary amine features.*
FDA Label Image

Fig1 (Fig1 Slc 0054)

Fig1 (Fig1 Slc 0054)
An illustration diagram showing the five labeled layers of a Buprenorphine transdermal extended release patch: 1) Backing Layer, 2) Overlapping Adhesive Film, 3) Separating Layer, 4) Drug/Polymer Adhesive Matrix, and 5) Peel-off Release Liner.*
FDA Label Image

Fig2 (Fig2 Slc 0054)

Fig2 (Fig2 Slc 0054)
A line graph showing plasma concentration of Buprenorphine over time after repeated dosing with a 10 mcg/hour transdermal patch every 7 days for 3 cycles. The x-axis represents time in days (0 to 26), and the y-axis shows concentration in pg/mL (0 to 350). The graph includes data points with error bars and a marker indicating the time of patch removal.*
FDA Label Image

Fig3 (Fig3 Slc 0054)

Fig3 (Fig3 Slc 0054)
A line graph comparing the percentage of patients improved at different levels of pain reduction for Buprenorphine TDS 10/20 versus placebo. The x-axis represents the percent of reduction/improvement in pain ranging from >0% to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Buprenorphine shows a generally higher percentage of patients improved compared to placebo across the pain reduction spectrum.*
FDA Label Image

Fig4 (Fig4 Slc 0054)

Fig4 (Fig4 Slc 0054)
A line graph comparing the percentage of patients improved at various levels of pain reduction or improvement for Buprenorphine transdermal system (TDS) 5 and TDS 20. The x-axis shows percent of reduction or improvement in pain from >0% up to 100%, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%.*
FDA Label Image
FDA Label Image

Logo (Logo01)

FDA Label Image

Image Description (Figa Slc 0054)

Image Description (Figa Slc 0054)
Illustration showing recommended placement locations of a buprenorphine transdermal patch on the human body. Positions include the upper arm (both sides), upper chest, upper back, and side torso under the arm, indicating areas suitable for patch application.*
FDA Label Image

Image Description (Figb Slc 0054)

Image Description (Figb Slc 0054)
Illustration showing the application site for the Buprenorphine transdermal patch on the upper back, indicating placement near the shoulder blade on a presumably male figure.*
FDA Label Image

Image Description (Figc Slc 0054)

Image Description (Figc Slc 0054)
An instructional illustration labeled Figure C showing a person applying a Buprenorphine transdermal patch to the upper chest area, demonstrating the proper placement site for the patch.*
FDA Label Image

Image Description (Figd Slc 0054)

Image Description (Figd Slc 0054)
Figure D is a black and white instructional illustration showing two hands cutting a patch with scissors. The image demonstrates the action of trimming a Buprenorphine transdermal extended-release patch, highlighting proper handling before use.*
FDA Label Image

Image Description (Fige Slc 0054)

Image Description (Fige Slc 0054)
An instructional illustration labeled Figure E showing a buprenorphine transdermal patch with labeled parts: the patch itself, foil backing, and a foil handle used for peeling the backing off. This diagram visually explains the patch removal from its packaging.*
FDA Label Image

Image Description (Figf Slc 0054)

Image Description (Figf Slc 0054)
An instructional illustration showing two hands peeling back the protective liner from a rectangular transdermal patch, demonstrating the step to prepare the patch for application.*
FDA Label Image

Image Description (Figg Slc 0054)

Image Description (Figg Slc 0054)
An illustration showing a person applying a transdermal patch to the upper chest area, demonstrating the proper placement for a Buprenorphine extended-release patch. The person is depicted holding the patch near the chest, indicating how to position it on the skin.*
FDA Label Image

Image Description (Figh Slc 0054)

Image Description (Figh Slc 0054)
Illustration showing a person applying a transdermal patch to the chest area. The image is a simple line drawing labeled as Figure H, demonstrating how to place the patch on the skin, relevant to the use of a Buprenorphine extended-release transdermal patch.*
FDA Label Image

Image Description (Figi Slc 0054)

Image Description (Figi Slc 0054)
An instructional illustration showing a person applying a transdermal patch to the upper chest area. The figure is labeled as Figure 1 and visually demonstrates the proper placement of a Buprenorphine extended-release patch on the skin.*
FDA Label Image

Image Description (Figj Slc 0054)

Image Description (Figj Slc 0054)
Illustration showing hands removing a Buprenorphine transdermal patch from its packaging strip. The image depicts the step of peeling the adhesive strip to expose the patch before application.*
FDA Label Image

Image Description (Figk Slc 0054)

Image Description (Figk Slc 0054)
A black-and-white line illustration labeled 'Figure K' showing two hands holding a rectangular object, demonstrating an action likely related to the use or application of a transdermal patch.*
FDA Label Image

Image Description (Figl Slc 0054)

Image Description (Figl Slc 0054)
An instructional illustration showing hands removing the adhesive strip from a Buprenorphine transdermal patch package. The figure, labeled as Figure L, demonstrates the step of peeling off the adhesive to expose the patch for application.*
FDA Label Image

Image Description (Figm Slc 0054)

Image Description (Figm Slc 0054)
An instructional diagram showing hands peeling apart a patch's protective backing, with a portion of text visible on the patch. The image is labeled as Figure M, illustrating the step of removing the protective layer before applying the patch.*
FDA Label Image

Image Description (Fign Slc 0054)

Image Description (Fign Slc 0054)
An instructional diagram labeled Figure N showing a hand discarding a folded item into a trash receptacle, illustrating proper disposal method.*
FDA Label Image

Image Description (Figo Slc 0054)

Image Description (Figo Slc 0054)
An instructional line drawing depicting a hand holding a square object above a toilet bowl with the lid and seat raised, labeled as Figure 0. The image appears to show disposal instructions for the product packaging or patch.*
FDA Label Image

Image Description (Logo02)

FDA Label Image

Carton-10mcg (Carton 5mcg)

Carton-10mcg (Carton 5mcg)
Packaging label for Buprenorphine Transdermal System 5 mcg/hour patch, extended-release transdermal system. The carton contains 4 transdermal systems and 4 disposal units. Distributed by Ingenus Pharmaceuticals, LLC. The label emphasizes the 5 mcg/hour dosage strength multiple times and includes areas for affixing pharmacy labels and medication guides.*
FDA Label Image

Carton-7.5mcg (Carton 7.5mcg)

Carton-7.5mcg (Carton 7.5mcg)
Packaging label for Buprenorphine Transdermal System 7.5 mcg/hour extended-release patch by Ingenus Pharmaceuticals, LLC. The label mentions a package containing 4 transdermal systems and 4 disposal units, intended for use in opioid-experienced patients only. The label includes safety warnings and dosage form details for transdermal delivery.*
FDA Label Image

Carton-10mcg (Carton 10mcg)

Carton-10mcg (Carton 10mcg)
Packaging label for Buprenorphine Transdermal System 10 mcg/hour by Ingenus Pharmaceuticals, LLC. The label indicates a transdermal patch for systemic delivery of 10 mcg per hour for seven days. The package contains 4 transdermal systems and 4 disposal units. It is intended for use in opioid-experienced patients only and includes storage instructions and dispensing precautions.*
FDA Label Image

Carton-15mcg (Carton 15mcg)

Carton-15mcg (Carton 15mcg)
Packaging label for Buprenorphine Transdermal System 15 mcg/hour patch, extended-release, transdermal dosage form. The box indicates it contains 4 transdermal systems (patches) and one package of 4 disposal units. Labeler is Ingenus Pharmaceuticals, LLC. The label includes prescription-only status and opioid-use warnings.*
FDA Label Image

Carton-20mcg (Carton 20mcg)

Carton-20mcg (Carton 20mcg)
Packaging label for Buprenorphine Transdermal System 20 mcg/hour, an extended-release transdermal patch. The label shows a carton containing 4 patches (4 transdermal systems) in one package of 4 disposal units. Manufactured by Ingenus Pharmaceuticals, LLC, the label includes a barcode, storage instructions, and a designated area to affix a pharmacy label. The product is intended for opioid-experienced patients only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.